More tools:Markets·Screener·Research·Chat

MBX Biosciences, Inc. Common Stock (MBX) Financial Statements

MBX Biosciences, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00W7W53N4
XNAS · usd
62.99▲ 1.27 (2.06%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close61.72
Day's Range60.66 – 64.17
52-Week Range9.63 – 72.64
Volume266.0K
Avg Volume430.3K
Share Statistics
Shares Outstanding
Employees63
ExchangeXNAS
Listed2024-09-13
Share count as of August 3, 2026
Loading Income Statement…
Key questions about MBX Biosciences, Inc. Common Stock (MBX)
What is MBX Biosciences, Inc. Common Stock's Market Cap?
MBX Biosciences, Inc. Common Stock's Market Cap is $3.0B, based on as-reported figures from SEC (XBRL) filings.
What is MBX Biosciences, Inc. Common Stock's Enterprise Value?
MBX Biosciences, Inc. Common Stock's Enterprise Value is $2.6B, based on as-reported figures from SEC (XBRL) filings.
What is MBX Biosciences, Inc. Common Stock's EV / EBITDA?
MBX Biosciences, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is MBX Biosciences, Inc. Common Stock's Net Income (TTM)?
MBX Biosciences, Inc. Common Stock's Net Income (TTM) is -$104.3M, based on as-reported figures from SEC (XBRL) filings.
What is MBX Biosciences, Inc. Common Stock's EBITDA?
MBX Biosciences, Inc. Common Stock's EBITDA is -$117.7M, based on as-reported figures from SEC (XBRL) filings.
What is MBX Biosciences, Inc. Common Stock's Diluted EPS (TTM)?
MBX Biosciences, Inc. Common Stock's Diluted EPS (TTM) is -2.17, based on as-reported figures from SEC (XBRL) filings.
What is MBX Biosciences, Inc. Common Stock's Net Debt?
MBX Biosciences, Inc. Common Stock's Net Debt is -$418.6M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
Operating expenses
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest and other income, net
Net loss
Net loss attributable to common stockholders
Net loss per common share, basic
Net loss per common share, diluted